Neuroptix Corporation


Clinical Advisory Board

P. Murali Doraiswamy, MD
Professor, Psychiatry & Behavioral Sciences
Duke University Institute for Brain Sciences,
Durham, North Carolina

A renowned expert on brain longevity and mental health, Dr. Doraiswamy is head of Duke University’s Biological Psychiatry division and a Senior Fellow at Duke’s Center for the Study of Aging. As Director of Psychiatry Clinical Trials at Duke for nearly ten years, he received numerous awards for his work as an investigator on landmark studies. The author of more than two hundred scientific articles, Dr. Doraiswamy has served as an adviser to the Food and Drug Administration, the American Federation for Aging Research, the National Institutes of Aging, and the World Health Organization, as well as leading Alzheimer’s medical journals and advocacy groups. His research has been featured in The Wall Street Journal, USA Today, and The New York Times, and on CBS News, The Today Show, NPR, and the BBC. He has written several popular books, among them — The Alzheimer’s Action Plan: The Experts’ Guide to the Best Diagnosis and Treatment for Memory Problem.

Barry D. Greenberg, PhD
Director, Neuroscience Drug Discovery and Development
University Health Network (UHN)
Toronto, Ontario, Canada

Dr. Barry Greenberg has been involved in Alzheimer’s Disease research and drug discovery since 1985. Dr. Greenberg is Director of Neuroscience Drug Discovery & Development at University Health Network (UHN), Toronto; and, Director of Strategy, Toronto Dementia Research Alliance (TDRA), which includes an academic coalition of the five memory/dementia clinics affiliated with the University of Toronto (Baycrest, CAMH, St. Michael’s Hospital, Sunnybrook Hospital, and University Health Network) together with the Faculty of Medicine of the University. Before joining UHN as Director of Neuroscience Drug Discovery and Development, he was Senior Director of Pharmacology at Neurochem, responsible for the preclinical biology research program and a contributor to the analyses of the phase III Alzhemed trial.  At UHN, he is also Strategy Director of the Toronto Dementia Research Alliance, a consortium involving academic research and the five memory clinics at hospitals affiliated with the University of Toronto, to create a citywide dementia research center. Dr. Greenberg  has authored or co-authored 70 articles in peer-reviewed journals and 19 book chapters and reviews.

Carl H. Sadowsky, M.D., F.A.A.N.
Director of Research at Premiere Research Institute
Clinical Professor, Division of Neurology, Nova Southeastern University, Fort Lauderdale, Florida

Dr. Sadowsky received his medical degree from Cornell University’s Weill Medical College. He completed an internship and residency in internal medicine and a residency in neurology, including a chief residency at Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Dr. Sadowsky served as a United States Air Force Major and Chief of Neurology of the United States Air Force Hospital in Wiesbaden, Germany, from 1976-1979. Dr. Sadowsky has participated in numerous trials evaluating the safety and efficacy of various cholinesterase inhibitors in the treatment of Alzheimer’s Disease (AD), a primary focus of his research efforts. He is a frequent presenter at medical meetings and symposia and a prolific writer. His articles, which have appeared in such prestigious journals as the Journal of the American Medical Association, Neurology, and Archives of Neurology, have most recently focused on comparisons of agents used in the treatment of patients with AD, the molecular mechanisms of AD, imaging in dementia, and ethical issues associated with patient care. A Fellow of the American Academy of Neurology, Dr. Sadowsky is a board member of the Southeast Florida Alzheimer’s Association and on the scientific review board for the Alzheimer's Drug Discovery Foundation. He has been selected by Best Doctors in America for 12 consecutive years.

Pierre N. Tariot, M.D.
Director of Banner Alzheimer’s Institute in Phoenix
Research Professor of Psychiatry at the University of Arizona College of Medicine

Dr. Tariot is a Phi Beta Kappa graduate of Amherst College who attended the University of Rochester School of Medicine and Dentistry.  He completed residencies in Internal Medicine and Psychiatry at the University of Wisconsin in Madison, Wisconsin, and is Board Certified in both specialties, with added qualifications in geriatrics.  He served as a Medical Staff Fellow and then Senior Staff Fellow at the Intramural Research Program of the National Institute of Mental Health.  In 1986, he joined the faculty of the University of Rochester Medical Center, achieving the rank of Professor of Psychiatry, Medicine, Neurology, and Aging and Developmental Biology.  He served as Director of the Memory Disorders Clinic, Director of Psychiatry at Monroe Community Hospital, and Director of the University of Rochester component of the Alzheimer’s Disease Cooperative Study, funded by the National Institute on Aging.  Since 2006, he has been at the Banner Alzheimer’s Institute, where he serves as Director.   Together with his colleague and friend, Eric Reiman, he serves as co-director of the Alzheimer’s Prevention Initiative.  This is a major new effort to identify interventions that may delay or even prevent the onset of Alzheimer’s.  The cornerstone project of this Initiative is a multinational presymptomatic trial in cognitively normal people at certain risk for developing Alzheimer’s disease because of their genetic background, which received NIH and other funding in May 2012. 

Gordon Wilcock, DM, FRCP, (Hon) DSc
Professor Emeritus of Clinical Geratology
Nuffield Department of Medicine
University of Oxford

Professor Wilcock is an Emeritus Professor at the University of Oxford. He is an internationally recognized leader in the field of Alzheimer’s disease.  Prof. Wilcock qualified in medicine in Oxford and was appointed to a Consultant post there in 1976, where his interest in dementia research started. He set up one of the first multidisciplinary research memory clinics in the UK, if not the first, in 1979. He was the founding chairman of the UK Alzheimer's Society and is currently a Vice President of that society. In 1984 he moved to Bristol, to take up the Chair in Care of the Elderly at the University, establishing an internationally recognized Alzheimer’s disease research program covering the spectrum from laboratory research at one end, to improving clinical care at the other, including both the development of treatments and the organization of care service delivery. He returned to Oxford in June 2006 to the post of Professor of Geratology, where he established a clinical dementia research program in the John Radcliffe Hospital. He has also contributed to the National Dementia Strategy for England, as well as numerous national and international organizations in the field of dementia research and service provision.